Serum lipids and Lipoproteins in type 2 diabetes

Abstract

ABSTRACT. Serum lipids, lipoproteins and lipolytic enzymes were studied (a) before and (b) after six weeks of glipizide treatment in ten (4 men, 6 women) newly diagnosed type 2 diabetic patients. Improved glycemic control during glipizide therapy (HbA1:11.2±0.5 % vs 9.6 ± 0.4%;P<0.01)had no effect on serum or lipoprotein triglyceride, whereas both serum total cholesterol (4.60 ± 0.29 mmol/l vs 4.37 ± 0.30 mmol/l; P<0.05) and LDL cholesterol (3.16 ± 0.18 mmol/l vs 2.98 ± 0.24 mmol/l; P<0.05) decreased after six weeks of glipizide. HDL cholesterol, the composition and concentration of HDL subfractions HDL2 and HDL3 and lipolytic enzymes were uninfluenced by glipizide therapy. In conclusion, low HDL levels in type 2 diabetic patients do not appear to be due to sulphonylurea treatment, but rather represent a basic abnormality of HDL metabolism.